- Research article
- Open Access
A novel approach in the treatment of neuroendocrine gastrointestinal tumors: Additive antiproliferative effects of interferon-γ and meta-iodobenzylguanidine
BMC Cancer volume 4, Article number: 23 (2004)
Therapeutic options to effectively inhibit growth and spread of neuroendocrine gastrointestinal tumors are still limited. As both meta-iodobenzylguanidine (MIBG) and interferon-γ (IFNγ) cause antineoplastic effects in neuroendocrine gastrointestinal tumor cells, we investigated the antiproliferative effects of the combination of IFNγ and non-radiolabeled MIBG in neuroendocrine gut STC-1 and pancreatic carcinoid BON tumor cells.
Methods and results
IFNγ receptors were expressed in both models. IFNγ dose- and time-dependently inhibited the growth of both STC-1 and of BON tumor cells with IC50-values of 95 ± 15 U/ml and 135 ± 10 U/ml, respectively. Above 10 U/ml IFNγ induced apoptosis-specific caspase-3 activity in a time-dependent manner in either cell line and caused a dose-dependent arrest in the S-phase of the cell cycle. Furthermore, IFNγ induced cytotoxic effects in NE tumor cells.
The NE tumor-targeted drug MIBG is selectively taken up via norepinephrine transporters, thereby specifically inhibiting growth in NE tumor cells. Intriguingly, IFNγ treatment induced an upregulation of norepinephrine transporter expression in neuroendocrine tumors cells, as determined by semi-quantitative RT-PCR. Co-application of sub-IC50 concentrations of IFNγ and MIBG led to additive growth inhibitory effects, which were mainly due to increased cytotoxicity and S-phase arrest of the cell cycle.
Our data show that IFNγ exerts antiproliferative effects on neuroendocrine gastrointestinal tumor cells by inducing cell cycle arrest, apoptosis and cytotoxicity. The combination of IFNγ with the NE tumor-targeted agent MIBG leads to effective growth control at reduced doses of either drug. Thus, the administration of IFNγ alone and more so, in combination with MIBG, is a promising novel approach in the treatment of neuroendocrine gastrointestinal tumors.
Gastrointestinal neuroendocrine (NE) tumors represent a rare and rather heterogeneous tumor entity. Almost half of the metastatic NE gastrointestinal tumors release excessive amounts of biogenic amines and/or neuropeptides thereby causing a characteristic hypersecretion syndrome. The often bizarre clinical symptoms are generally well controlled by somatostatin analogues or interferon-α (IFNα) [1, 2]. However, further growth and spread is generally not prevented on the long by either biotherapy or conventional chemotherapy. Thus, innovative treatment strategies should be developed that are both effective and well tolerated.
A promising approach for novel treatment of NE gastrointestinal tumor disease may be the modulation of the IFNγ-receptor system. The immunomodulatory lymphokine IFNγ modulates biological responses by binding to its cognate receptor thereby activating members of a transcription factor family termed STAT (signal transducers and activators of transcription) . IFNγ-induced STAT signaling and STAT-associated induction of interferon regulatory factors (IRFs) have been shown to exert key regulatory function for proliferation, differentiation and survival . The underlying mechanisms of IFNγ-induced growth inhibition show a broad spectrum, including the induction of cell cycle arrest, apoptosis and cytotoxcicity [5, 6].
Although interferons are known to evoke growth regulatory effects in many tissues, the effectiveness of IFN-induced growth inhibition varies between the various cell types. Thus, growth control observed in a given cell type does not allow to predict similar effects of IFNγ on tissues of other origin .
IFNγ-induced growth inhibition in NE gastrointestinal tumors has not yet been evaluated in great detail. Here we examine the antineoplastic potency of IFNγ alone or in combination with non-radiolabeled MIBG in NE gastrointestinal tumor cells of the gut and pancreas.
In its radiolabeled form the norepinephrine analog MIBG is an established diagnostic and therapeutic agent in neuroendocrine tumors expressing plasma membrane bound norepinephrine transporters [8–10]. Recently, we and others could show that even its non-radiolabeled form, the so-called "cold MIBG" can effectively inhibit the growth of neuroendocrine tumor cells [11, 12]. Since IFNγ has been reported to upregulate the MIBG-transporting norepinephrine transporter in neuroblastoma cells , it was intriguing to evaluate, whether this also held true for NE gastrointestinal tumors cells and whether such an upregulation could boost the antineoplastic potency of cold MIBG in NE tumor cells.
Human pancreatic carcinoid BON cells [14, 15] were maintained in a 1:1 mixture of DMEM, and F12K medium containing 10% FCS (Biochrom, Berlin, Germany) and 1% L-glutamine. The murine intestinal neuroendocrine tumor cell line STC-1, which was a gift from Dr. D. Hanahan (University of California, San Francisco, CA), was maintained in DMEM supplemented with 15% horse serum (Biochrom, Berlin, Germany), 2.5% FCS (Biochrom) and 1% L-glutamine . The neuroendocrine-differentiated human colorectal cancer cell line Colo 320 DM  was maintained in standard RPMI 1640 medium, complemented with 10% FCS. All cell lines were kept at 37°C in a humidified atmosphere (5% CO2).
IFNγ and non-radiolabeled meta-iodobenzylguanidine (MIBG) were purchased from Sigma (München, Germany). Stock solutions were prepared in water or DMSO, respectively, and stored at -20°C. The drugs were diluted in fresh media before each experiment. In all experiments, the final DMSO concentration was <0.5%. To evaluate the effects of IFNγ and/or MIBG, cells were incubated with either control medium or medium containing rising concentrations of the respective drugs. Media were changed daily to ensure constant drug concentrations in the incubation medium.
Semi-quantitative analysis of mRNA expression of the human plasma membrane bound norepinephrine transporter (hNET) and the housekeeping gene β-actin was carried out by RT-PCR with the number of cycles at which the band intensity increased linearly with the amount of mRNA used .
Total RNA was extracted from cultured cell lines with RNAClean following the recommendation of the manufacturer (Hybaid, London, UK). Reverse transcription and PCR reactions were carried out as described elsewhere in detail . To eliminate any possible contamination with genomic DNA, RNAs were treated with 1 U DNAse I (Gibco, Karlsruhe, Germany) per μg RNA for 15 min at room temperature. Purified RNA was reverse transcribed into cDNA using oligo-dT-primers and the SuperScript Preamplification-Kit (Gibco). PCR reactions were carried out in a total volume of 50 μl containing 400 nM of each primer, 200 μM of each dNTP (Pharmacia, Uppsala, Sweden), 50 mM KCl, 1.5 mM MgCl2, 10 mM Tris and 1 U Taq-Polymerase (Pharmacia). PCR was performed in a Peltier thermocycler (PTC-200, MJ Research, Watertown, MA) with primers and at the conditions indicated in table 1.
Measurement of growth inhibition
Changes in cell number of BON and STC-1 cells were determined by crystal violet staining after incubation with rising drug concentrations (IFNγ: 0–500 U/ml; MIBG: 0–100 μM) for up to 5 days. Measurements were performed as described . Cells were washed with PBS and fixed with 1% glutaraldehyde. After another washing step, cells were stained with 0.1% crystal violet. The unbound dye was removed by washing. Crystal violet that had absorbed onto the cells was solubilized with 0.2% Triton X-100. Then light extinction was analyzed at 570 nm using an ELISA reader.
Cell cycle analysis
Cell cycle analysis was performed by the method of Vindelov and Christensen, as described previously . Cells were trypsinized, washed, and the nuclei were isolated using CycleTest PLUS DNA Reagent Kit (Becton Dickinson, Heidelberg, Germany). DNA was stained with propidium iodide according to the manufacturers' instructions. The DNA content of the nuclei was detected by flow cytometry and analyzed using CellFit software (Becton Dickinson, Heidelberg, Germany).
Caspase-3 activity assay
To determine apoptosis the activity of caspase-3, a key enzyme in the apoptotic cascade was measured. Preparation of cell lysates and determination of caspase-3 activity was performed as described previously . The activity of caspase-3 was calculated from the cleavage of the fluorogenic substrate DEVD-AMC (Calbiochem-Novabiochem, Bad Soden, Germany). Cell lysates were incubated with substrate solution (caspase-3 substrate AC-DEVD-AMC 20 μg/ml, HEPES 20 mM, glycerol 10%, DTT 2 mM, pH 7.5) for 1 h at 37°C, and the cleavage of DEVD-AMC was measured fluorometrically with a VersaFluor fluorometer (excitation: 360 nm emission: 460 nm) from Biorad, Munich, Germany.
Determination of cytotoxicity
Cells were seeded at a density of 5,000 cells/well into 96-well microtiter plates and incubated with IFNγ (0–500 U/ml) or MIBG (0–50 μM) or the combination of both. Release of the cytoplasmic enzyme lactate dehydrogenase (LDH), indicating cytotoxicity, was measured after 48 h of incubation by using the colorimetric kit from Roche as described elsewhere [20, 23]. Background release obtained by measuring LDH release of untreated cells was subtracted. Maximum release of LDH was obtained by adding 100 μl of 2% Triton X-100 to untreated cells. For determinations, 100 μl of each sample were transferred to a 96-well microtiter plate; 100 μl of LDH assay reagent were added to each well and incubated for 30 min at room temperature in the dark. The absorbance of samples was then measured at 490 nm. No significant LDH release was detected in the tissue culture medium alone nor in drug-containing incubation medium.
The antineoplastic effects of the various substances and vehicles were compared by the unpaired, two-tailed Mann-Whitney U-test. The unpaired student t-test was used for cell cycle analysis. P values were considered to be significant at <0.05. If not stated otherwise, all functional experiments were performed in quadruplicate.
Expression of IFNγ receptors in NE gastrointestinal tumor cells
To monitor IFNγ receptors (IFNγR) in human pancreatic carcinoid BON cells, mRNA expression of IFNγR was evaluated by RT-PCR. Using specific primers directed against the α-chain of the human IFNγR , we detected a robust expression of PCR-amplificates of the expected size (Fig. 1). The neuroendocrine-differentiated colorectal carcinoma cell line Colo320 DM served as a positive control. IFNγR expression in murine intestinal NE STC-1 tumor cells has already been demonstrated by cDNA array analysis .
Growth inhibition by IFNγ
Changes in cell number induced by IFNγ were studied by performing crystal violet assays. IFNγ (0–500 U/ml) time- and dose-dependently inhibited the growth of both BON and STC-1 cells. After 5 days of incubation a decrease in cell number of up to 90% was observed in BON cells (Fig. 2a). In slower growing STC-1 cells a decrease of up to 75% was observed after 5 days of incubation (Fig. 2b). The IC50 values of IFNγ, determined after 72 h of incubation, amounted to 135 ± 10 U/ml in BON cells and 95 ± 15 U/ml in STC-1 cells.
Additive antiproliferative effects of IFNγ and MIBG
Recently, we showed that non-radiolabeled MIBG specifically inhibited the growth of norepinephrine transporter (NET)-expressing STC-1 tumor cells (IC50 ~ 8 μM) and that MIBG-treatment increased the expression of IFNγ receptors. Vice versa, IFNγ also enhanced MIBG-uptake . Hence, we additionally evaluated antiproliferative effects of a combination treatment of NE gastrointestinal tumor cells with IFNγ and MIBG.
In STC-1 cells sub-IC50 concentrations of IFNγ (10–100 U/ml) and MIBG (1–5 μM) produced impressive additive growth inhibitory effects (Fig. 3a). The combination of 100 U/ml IFNγ with 5 μM MIBG decreased the proliferation of STC-1 cells by 95%. Such an antiproliferative effect was reached by MIBG alone only with concentrations of at least 25 μM.
Using RT-PCR we also demonstrated the expression of plasma membrane bound NET in BON cells which had not yet been investigated with regard to NET expression (Fig. 4a). Proliferation assays revealed that MIBG (1–100 μM) dose- and time-dependently inhibited the growth of BON cells by up to 68 ± 3.4%. The IC50 value of MIBG, determined after 48 h of incubation, amounted to 47.4 ± 2.1 μM being distinctly higher than in STC-1 cells. Pretreating BON cells with IFNγ (10–500 U/ml) influenced the expression of MIBG-transporting NET. Semiquantitative RT-PCR revealed an IFNγ-induced increase of NET expression in BON cells by up to 200% after 48 h (Fig. 4b). However, upregulation of NET expression did not result in an overadditive antiproliferative effect of IFNγ (10–100 U/ml) plus MIBG (10–20 μM). Like in STC-1 cells, additive antiproliferative effects of IFNγ and MIBG were observed in BON cells (Fig. 3b). The combination of 100 U/ml IFNγ with 10 μM MIBG produced antiproliferative effects that were comparable to those achieved by 50 μM MIBG on its own.
IFNγ and cell cycle regulation
Flow cytometric analysis revealed that challenging BON cells for 48 h with rising concentrations of IFNγ (0–500 U/ml) dose-dependently arrested the cells in the S-phase of the cell cycle, thereby decreasing the proportion of cells in the G2/M-phase. S-phase arrest was significant for 250–500 U/ml IFNγ (Fig. 5). The effect of MIBG treatment on the cell cycle of BON cells was also evaluated. In contrast to slow-growing STC-1 cells, not displaying cell cycle arresting effects in response to MIBG-treatment , BON cells showed a significant and dose-dependent arrest in the G0/G1-phase of the cell cycle after treatment with MIBG (10–50 μM). Accordingly, the proportion of cells in the G2/M-phase decreased.
Co-application of IFNγ (10–100 U/ml) and MIBG (50 μM) resulted in an abrogation of the MIBG-induced G0/G1-phase arrest, while the proportion of cells in the S-phase significantly increased as compared to MIBG-treatment alone. Interestingly, the S-phase arrest induced by combination treatment with 100 U/ml IFNγ and 50 μM MIBG was as strong as the one achieved by 500 U/ml IFNγ alone (Fig. 5).
Proapoptotic effects of IFNγ
To check whether an induction of programmed cell death contributed to the antineoplastic effects of IFNγ, we investigated IFNγ-induced activation of caspase-3, a key enzyme in the apoptotic signaling pathway. Above 10 U/ml IFNγ induced caspase-3 activation in both STC-1 and BON cells after 48 h of incubation (Fig. 6a). No significant increase in IFNγ-induced caspase-3 activity was observed at concentrations higher than 100 U/ml or 250 U/ml IFNγ. Unexpectedly, co-treatment with IFNγ (10–100 U/ml) plus MIBG (1–2 μM for STC-1 cells; 10–20 μM for BON cells) led to subadditive caspase-3 activation in either BON or STC-1 cells (Fig 6b,6c).
Cytotoxic loss of cellular membrane integrity was measured by LDH release assay. Incubating BON cells with 10–500 U/ml IFNγ for 48 h resulted in a pronounced and dose-dependent increase in LDH release (Fig. 7a). Additionally, we analyzed MIBG-induced cytotoxicity in BON cells. Treatment with MIBG for 48 h also dose-dependently increased the LDH-release of BON cells (Fig. 7b). The combination of IFNγ (10–100 U/ml) and MIBG (10–50 μM) resulted in a marked overadditive LDH release from BON cells (Fig. 7c). Compared to the calculated values of an assumed additive cytotoxicity (indicated as black bars in the columns of Fig. 7c), the actual LDH-release induced by 100 U/ml IFNγ plus 50 μM MIBG was about 32 ± 4% higher than the calculated sum. The combination of the lowest doses of IFNγ (10 U/ml) and MIBG (10 μM) surmounted the calculated sum of each effect by 188 ± 12%. Thus, the cytotoxic effect of a "low-dose combination" of IFNγ and MIBG was as pronounced as the one obtained by 500 U/ml IFNγ alone.
Although excellent control of tumor-associated hypersecretion syndromes of neuroendocrine gastrointestinal tumors can be achieved by biotherapy with somatostatin analogs or IFNα, systemic treatment options to inhibit the growth and further spread of metastatic neuroendocrine tumors are still unsatisfactory. For instance, IFNα although excellently controling hypersecretion in most cases , has been shown to cause only a partial tumor remission in less than 20% of treated patients [1, 7, 26]. Novel treatment modalities are therefore needed.
Here, we report on the antineoplastic effects of IFNγ, a cytokine which has already been shown to exert growth inhibitory effects in vitro in several non-neuroendocrine cancer models, including breast , hepatocellular , ovarian  and colorectal carcinoma [30, 31] or glioblastoma . Also in vivo, IFNγ has been demonstrated to be beneficial as a first line therapeutic agent for ovarian cancer  or as a supportive drug for enhanced chemoimmunotherapeutic regimes of metastatic melanoma . Nevertheless, in other cancers (i.e., renal cell carcinoma or SCLC) IFNγ did not show any appreciable beneficial antineoplastic action in man [35, 36], arguing for a distinctive tumor species-dependent effect of the cytokine. As IFNγ-mediated growth control of a particular tumor type does apparently not allow to predict similar effects in other tumor species, it was all the more important to investigate IFNγ's antineoplastic action in neuroendocrine gastrointestinal tumor cells. Here we provide evidence that IFNγ potently inhibits growth of neuroendocrine gastrointestinal tumor cells. When IFNγ was combined with MIBG, an even more pronounced antiproliferative effect was obtained.
As the growth pattern of NE gastrointestinal tumors exhibits a wide spectrum ranging from very slow to fast growing types , it was important to study IFNγ-induced growth inhibition in NE tumor cell lines with different growth characteristics and of different origin. We chose two models of NE gastrointestinal tumor disease: First, human pancreatic carcinoid BON cells with a doubling time of 34 h, and second, NE tumor cells of the gut (STC-1 cells) with a doubling time of 54 h . In either NE tumor model we observed growth inhibitory effects of IFNγ with IC50 values of about 100 U/ml and maximal growth inhibition by 75–90% at ≥250 U/ml IFNγ. As these concentrations are within the therapeutically achievable range of IFN-plasma levels in humans , IFNγ appears to be a promising agent for innovative growth inhibition of NE gastrointestinal tumor cells.
The signaling pathways mediating IFNγ's antineoplastic action differ between various tumor types and lead to distinct biological responses, such as G1-arrest , S-phase arrest [40, 41], induction of apoptosis [24, 28] and cytotoxicity .
To further characterize the antiproliferative action of IFNγ in NE gastrointestinal tumor cells, we performed cell cycle analyses. Flow cytometry with isolated nuclei of IFNγ-treated BON tumor cells, revealed a significant increase in the proportion of cells in the S-phase. Cell cycle arrest by IFNγ in the S-phase had previously been described for other tumors such as glioblastomas , but other reports described a G0/G1-arrest in response to IFNγ treatment [6, 7, 43]. The accumulation of NE gastrointestinal tumor cells in the S-phase of the cell cycle may be of great value for novel combination treatments with established antimetabolic chemotherapeutics such as 5-fluorouracil, which interfere with DNA-synthesis . Thus, the S-phase arresting cytostatic drug irinotecan enhances the antiproliferative efficacy of 5-fluorouracil in colon cancer .
Moreover, we observed an induction of apoptosis in neuroendocrine gastrointestinal tumor cells by IFNγ. Concerning the underlying mechanisms of IFNγ-induced apoptosis both indirect mechanisms like an increase in TNF-α sensitivity , an upregulation of CD95 receptor expression  or a modulation of human leukocyte antigen molecules (HLA) , and direct mechanisms like the upregulation and activation of caspases have been shown [24, 49]. In BON and STC-1 cells we found a dose-dependent induction of apoptosis via proapoptotic caspase-3 activation. This direct mechanism has been previously described by Detjen et al.  in neuroendocrine QGP-1 tumor cells. In OGP-1 cells IFNγ-mediated apoptosis was found to require intermediate signaling steps such as induction of the interferon regulatory factor IRF-1 and subsequent activation of the initiator caspase-1, which accounted for the relatively long time to response of IFNγ-induced apoptosis. Caspase-1-mediated activation of downstream caspases in response to IFNγ has been reported for other cell models, like leukemia cells , vascular smooth muscle cells  and HeLa cells . It is intriguing to speculate, that also in the BON and STC-1 tumor models IFNγ-mediated apoptosis involved such intermediary signaling steps, since caspase-3 activation in BON and STC-1 cells was not detectable earlier than after 48 h of incubation with IFNγ. In order to fully understand the signaling events of IFNγ-induced apoptosis in neuroendocrine tumor cells further investigations are required.
Growth inhibition of NE tumor cells by IFNγ also involves cytotoxcicity. At least at high concentrations of IFNγ, BON cells displayed a significant increase in LDH release. Interestingly, at the half-maximal growth inhibitory IFNγ concentration of 100 U/ml neither a significant increase in cytotoxicity nor a significant S-phase arrest could be observed, and only caspase-3 activity was significantly increased. Thus, at lower concentrations IFNγ appears to control growth of NE tumor cells mainly by apoptosis, whereas at higher concentrations other mechanisms are involved.
The second goal of our study was to explore the growth inhibitory effects of a combination treatment of IFNγ and non-radiolabeled meta-iodobenzylguanidine (MIBG). The rationale for investigating this particular combinbation was first, that non-radiolabeled MIBG was a potent NE tumor-specific antineoplastic drug [11, 38], and second, that IFNγ enhanced the uptake of MIBG by increasing the expression of norepinephrine transporters in neuroblastoma cells . Moreover, we recently showed that MIBG induced an overexpression of IFNγ-receptors in NE gastrointestinal tumor cells . These results suggested possible synergistic action of a combination treatment of IFNγ and MIBG. Intriguingly, combining sub-IC50 concentrations of IFNγ and MIBG led to growth inhibition of up to 95%. In STC-1 cells, the combination of IFNγ and MIBG exeeded the maximal antiproliferative effect of IFNγ alone by more than 20%. To achieve 90% growth inhibition of STC-1 cells by MIBG alone, concentrations beyond 25 μM were needed. Thus, combining IFNγ and MIBG allows to reduce the concentration of either agent to one fifth without losing excellent growth control. The same holds true for BON cells, which also displayed enhanced growth inhibition in response to sub-IC50 concentrations of IFNγ and MIBG. The potential of this novel combination treatment strategy will have to be evaluated in future clinical studies.
To further investigate underlying mechanisms of the proposed combination therapy, we evaluated IFNγ-induced norepinephrine transporter expression, apoptosis, cell cycle regulation and cytotoxicity in BON cells. Our results indicate that an overexpression of norepinephrine transporters does not account for enhanced growth inhibition by IFNγ plus MIBG. Although IFNγ induced the expression of norepinephrine transporters (NET) in neuroendocrine gastrointestinal tumor cells, the IFNγ concentrations required to achieve a marked increase in NET expression were far above the antiproliferative IC50-value of about 100 U/ml. Hence, our data indicate that an enhanced MIBG-uptake due to an IFNγ-induced overexpression of NET cannot be achieved with IFNγ concentrations, suitable for combination treatment.
Unexpectedly, the combination of MIBG and IFNγ resulted in a sub-additive caspase-3 activation as compared to treatment with either drug alone. Furthermore, we found an abrogation of MIBG-induced G0/G1-phase arrest in BON cells that had been co-treated with S-phase arresting IFNγ. Thus, MIBG and IFNγ appear to modulate distinct signaling pathways to induce apoptosis and cell cycle arrest in NE tumor cells. Due to yet unknown interferences in the signaling events, the effects on apoptosis and cell cycle were less pronounced and even sub-additive. Thus, it will be of future interest to identify the signaling molecules involved in this interference to gain insight into the underlying regulatory processes at the molecular level. However, sub-additive cell cycle arrest has already been found for other drug combinations, like the combination of 5-fluorouracil and cisplatin in colon cancer. In contrast to our findings the sub-additive cell cycle arrest of 5-fluorouracil and cisplatin led to a reduced growth inhibition than with 5-fluorouracil alone .
Despite of the reduced apoptosis and cell cycle arrest the growth inhibition obtained by IFNγ plus MIBG was additive in NE tumor cells. The most likely explanation of these conflicting results is a synergistic increase in cytotoxicity in resopnse to IFNγ plus MIBG. While almost no cytotoxicity was seen for either drug alone, the combination of low doses of MIBG and IFNγ led to a pronounced and significant synergistic increase in cytotoxicity. Concentrations as high as 500 U/ml were needed to achieve comparable cytotoxic effects by IFNγ alone. The underlying mechanisms are yet unknown, but have to be studied in the future. Anyway, the very fact, that co-treatment of NE tumor cells with IFNγ and MIBG exerts such a pronounced cytotoxic effect may be of potential clinical value: As the expression of MIBG-transporting norepinephrine transporters in extraneuronal locations is limited or low (e.g., heart, renal medulla, lung endothelial cells), the relative specific and exclusive NET (over)expression in neuroendocrine gastrointestinal tumor cells forms a basis for NE tumor-targeted treatment . Thus, a low concentration of MIBG renders an ineffective concentration of IFNγ cytotoxic in NE tumor cells. It can therefore be speculated that the combination of IFNγ with MIBG may induce a NE tumor cell-specific killing with reduced side-effects in normal cells. Future clinical studies will have to clarify the actual effects in vivo.
Our study provides evidence that IFNγ induces both cell cycle arrest and apoptosis in NE gastrointestinal tumor cells. Moreover, IFNγ can be effectively combined with non-radiolabeled MIBG in order to achieve excellent growth control at low concentrations of either drug. Thus, IFNγ represents a promising novel drug to be tested in patients with metastatic NE gastrointestinal tumor disease.
interferon regulatory factor
phosphate-buffered NaCl solution
reverse transcriptase-polymerase chain reaction
signal transducers and activators of transcription
Faiss S, Scherübl H, Riecken EO, Wiedenmann B: Drug therapy in metastatic neuroendocrine tumors of the gastroenteropancreatic system. Recent Results Cancer Res. 1996, 142: 193-207.
Öberg K: Chemotherapy and biotherapy in the treatment of neuroendocrine tumors. Ann Oncol. 2001, 12: S111-S114. 10.1023/A:1012465801251.
Bromberg J, Darnell JE: The role of STATs in transcriptional control and their impact on cellular function. Oncogene. 2000, 19: 2468-2473. 10.1038/sj.onc.1203476.
Meraz MA, White JM, Sheehan , Bach EA, Rodig SJ, Dighe AS, Kaplan DH, Riley JK, Greenlund AC, Campbell D, Carver-Moore K, DuBois RN, Clark R, Aguet M, Schreiber RD: Targeted disruption of the STAT-1 gene in mice rerveals unexpeted physiologic specificity in the JAK-STAT signaling pathway. Cell. 1996, 84: 431-442. 10.1016/S0092-8674(00)81288-X.
Burke F, Smith PD, Crompton MR, Upton C, Balkwill FR: Cytotoxic response of ovarian cancer cell lines to IFNγ is associated with sustained induction of IRF-1 and p21 mRNA. Br J Cancer. 1999, 80: 1236-1244. 10.1038/sj.bjc.6690491.
Hoshiya Y, Gupta V, Kawakubo H, Brachtel E, Carey JL, Sasur L, Scott A, Donahoe PK, Maheswaran S: Mullerian inhibiting substance promotes IFN gamma-induced gene expression and apoptosis in breast cancer cells. J Biol Chem. 2003, 278: 51503-51712. 10.1074/jbc.M307626200.
Läuffer JM, Zhang T, Modlin IM: Review article: current status of gastrointestinal carcinoids. Aliment Pharamcol Ther. 1999, 13: 271-287. 10.1046/j.1365-2036.1999.00479.x.
Hoefnagel CA, Voute PA, de Kraker J, Marcuse HR: Radionuclide diagnosis and therapy of neural-crest tumors using 131I-meta-iodobenzylguanidine. J Nucl Med. 1987, 28: 308-314.
Taal BG, Hoefnagel CA, Boot H, Olmos Valdes RAV, Rutgers M: Improved effect of [131I]-MIBG treatment by predosing with nonradiolabeled MIBG in carcinoid patients, and studies in xenografted mice. Ann Oncol. 2000, 11: 1437-1443. 10.1023/A:1026592025862.
Taal BG, Hoefnagel CA, Olmos Valdes RAV, Boot H, Beijnen JH: Palliative effect of meta-iodobenzylguanidine in metastatic carcinoid tumors. J Clin Oncol. 1996, 14: 1829-1238.
Höpfner M, Sutter AP, Beck N, Barthel B, Maaser K, Zeitz M, Scherübl H: Meta-iodobenzylguanidine induced growth inhibition and apoptosis of neuroendocrine gastrointestinal tumor cells. Int J Cancer. 2002, 101: 210-216. 10.1002/ijc.10553.
Zuetenhorst H, Taal B, Bootm H, Valdes Olmos R, Hoefnagel C: Long-term palliation in metastatic carcinoid tumors with varoius applications of meta-iodobenzylguanidin (MIBG): pharmacological MIBG, 131I-labelled MIBG and the combination. Eur J Gastroenterol Hepatol. 1999, 11: 1157-1164.
Montaldo PG, Raffaghello L, Guarnaccia F, Pistoia V, Garaventa A, Ponzoni M: Increase of metaiodobenzylguanidine uptake and intracellular half-life during differentiation of human neuroblastoma cells. Int J Cancer. 1996, 67: 95-100. 10.1002/(SICI)1097-0215(19960703)67:1<95::AID-IJC16>3.0.CO;2-B.
Lemmer K, Ahnert-Hilger G, Höpfner M, Hoegerle S, Faiss S, Grabowski P, Jockers-Scherübl M, Riecken EO, Zeitz M, Scherübl H: Expression of dopamine receptors and transporter in neuroendocrine gastrointestinal tumor cells. Life Sci. 2002, 71: 667-678. 10.1016/S0024-3205(02)01703-4.
Ahnert-Hilger G, Stadtbäumer A, Strübing C, Scherübl H, Schultz G, Riecken EO, Wiedenmann B: gamma-Aminobutyric acid secretion from pancreatic neuroendocrine cells. Gastroenterology. 1996, 110: 1595-1604.
Jansen A, Höpfner M, Herzig KH, Riecken EO, Scherübl H: GabaC receptors in neuroendocrine gut cells: a new GABA binding-site in the gut. Eur J Physiol. 2000, 441: 294-300. 10.1007/s004240000412.
Park JG, Herbert KO, Sugarbaker PH, Henslee JG, Chen TR, Johnson BE, Gadzar A: Characteristics of cell lines established from human colorectal carcinoma. Cancer Res. 1987, 47: 6710-6718.
Sutter AP, Maaser K, Barthel B, Scherubl H: Ligands of the peripheral benzodiazepine receptor induce apoptosis and cell cycle arrest in oesophageal cancer cells: involvement of the p38MAPK signalling pathway. Br J Cancer. 2003, 89: 564-572. 10.1038/sj.bjc.6601125.
Glassmeier G, Herzig KH, Höpfner M, Lemmer K, Jansen A, Scherübl H: Expression of functional GABAA receptors in cholecystokinin-secreting gut neuroendocrine murine STC-1 cells. J Physiol (Lond). 1998, 510: 805-814. 10.1111/j.1469-7793.1998.805bj.x.
Höpfner M, Maaser K, von Lampe B, Hanski C, Riecken EO, Zeitz M, Scherübl H: Growth inhibition and apoptosis induced by P2Y2-receptors in human colorectal carcinoma cells: Involvement of intracellular calcium and cyclic AMP. Int J Colorectal Dis. 2001, 16: 154-166. 10.1007/s003840100302.
Maaser K, Höpfner M, Jansen A, Weisinger G, Gavish M, Kozikowski AP, Weizman A, Carayon P, Riecken EO, Zeitz M, Scherübl H: Specific ligands of the peripheral benzodiazepine receptor induce apoptosis and cell cycle arrest in human colorectal cancer cells. Br J Cancer. 2001, 85: 1771-1780. 10.1054/bjoc.2001.2181.
Maaser K, Höpfner M, Kap H, Sutter AP, Barthel B, von Lampe B, Zeitz M, Scherübl H: Extracellular nucleotides inhibit growth of human oesophageal cancer cells via P2Y(2)-receptors. Br J Cancer. 2002, 86: 636-644. 10.1038/sj.bjc.6600100.
Decker T, Lohmann-Matthes ML: A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity. J Immunol Methods. 1988, 115: 61-69. 10.1016/0022-1759(88)90310-9.
Detjen KM, Farwig K, Welzel M, Wiedenmann B, Rosewicz S: Interferon gamma inhibits growth of human pancreatic carcinoma cells via caspase-1 dependent induction of apoptosis. Gut. 2001, 49: 251-261. 10.1136/gut.49.2.251.
Detjen KM, Welzel M, Farwig K, Brembeck FH, Kaiser A, Riecken EO, Wiedenmann B, Rosewicz S: Molecular mechanism of interferon alfa-mediated growth inhibition in human neuroendocrine tumor cells. Gastroenterology. 2000, 118: 735-748.
Öberg K: Interferons in the management of neuroendocrine GEP-tumors: a review. Digestion. 2000, 62: 92-97. 10.1159/000051862.
Yim JH, Ro SH, Lowney JK, Wu SJ, Connett J, Doherty GM: The role of interferon regulatory factor-1 and interferon regulatory factor-2 in IFN-gamma growth inhibition of human breast carcinoma cell lines. J Interferon Cytokine Res. 2003, 23: 501-511. 10.1089/10799900360708623.
Detjen KM, Murphy M, Welzel M, Farwig K, Wiedenmann B, Rosewicz S: Downregulation of p21waf/cip-1 mediates apoptosis of human hepatocellular carcinoma cells in response to interferon-γ. Exp Cell Res. 2003, 282: 78-89. 10.1016/S0014-4827(02)00011-3.
Seppanen M, Lin L, Punnonen J, Grenman S, Punnonen R, Vihko KK: Regulation of UT-OC-3 ovarian carcinoma cells by cytokines: inhibitory effects on cell proliferation and activation of transcription factors AP-1 and NF-kappaB. Eur J Endocrinol. 2000, 142: 393-401. 10.1530/eje.0.1420393.
Toth CA, Thomas P: The effect of interferon treatment on 14 human colorectal cancer cell lines: growth and carcinoembryonic antigen secretion in vitro. J Interferon Res. 1990, 10: 579-588.
Schiller JH, Bittner G, Storer B, Willson JK: Synergistic antitumor effects of tumor necrosis factor and gamma-interferon on human colon carcinoma cell lines. Cancer Res. 1987, 47: 2809-2813.
Kominsky S, Johnson HM, Bryan G, Tanabe T, Hobeika AC, Subramaniam PS, Torres B: IFN-gamma inhibition of cell growth in glioblastomas correlates with increased levels of cyclin dependent knase inhibitor p21waf/cip-1. Oncogene. 1998, 17: 2973-2979. 10.1038/sj.onc.1202217.
Windbichler GH, Hausmaninger H, Stummvoll W, Graf AH, Kainz C, Lahodny J, Denison U, Müller-Holzner E, Marth C: Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial. Br J Cancer. 2000, 82: 1138-1144. 10.1054/bjoc.1999.1053.
Propper DJ, Chao D, Braybrooke JP, Bahl P, Thavasu P, Balkwill F, Turley H, Dobbs N, Gatter K, Talbot DC, Harris AL, Ganesan TS: Low-dose IFN-gamma induces tumor MHC expression in metastatic malignant melanoma. Clin Cancer Res. 2003, 9: 84-92.
Dutcher JP, Fine JP, Krigel RL, Murphy BA, Schaefer PL, Ernstoff MS, Loehrer PJ: Stratification by risk factors predicts survival on the active treatment arm in a randomized phase II study of interferon-gamma plus/minus interferon-alpha in advanced renal cell carcinoma (E6890). Med Oncol. 2003, 20: 271-281. 10.1385/MO:20:3:271.
van Zandwijk N, Groen HJ, Postmus PE, Burghouts JT, ten Velde GP, Ardizzoni A, Smith IE, Baas P, Sahmoud T, Kirkpatrick A, Dalesio O, Giaccone G: Role of recombinant interferon-gamma maintenance in responding patients with small cell lung cancer. A randomised phase III study of the EORTC Lung Cancer Cooperative Group. Eur J Cancer. 1997, 33: 1759-1766. 10.1016/S0959-8049(97)00174-3.
Öberg K: Expression of growth factors and their receptors in neuroendocrine gut and pancreatic tumors, and prognostic factors for survival. Ann NY Acad Sci. 1994, 733: 46-55.
Höpfner M, Sutter AP, Gerst B, Zeitz M, Scherübl H: A novel approach in the treatment of neuroendocrine gastrointestinal tumours. Targeting the epidermal growth factor receptor by gefitinib (ZD1839). Br J Cancer. 2003, 89: 1766-1775. 10.1038/sj.bjc.6601346.
Amrani Y, Tliba O, Choubey D, Huang CD, Krymskaya VP, Eszterhas A, Lazaar AL, Panettieri RA Jr: IFN-gamma inhibits human airway smooth muscle cell proliferation by modulating the E2F-1/Rb pathway. Am J Physiol Lung Cell Mol Physiol. 2003, 284: L1063-71.
Sangfelt O, Erikson S, Grander D: Mechanisms of interferon-induced cell cycle arrest. Front Biosci. 2000, 5: D479-D487.
Vadiveloo PK, Vairo G, Novak U, Royston AK, Whitty G, Filonzi EL, Cragoe EJ, Hamilton JA: Differential regulation of cell cycle machinery by various antiproliferative agents linked to macrophage arrest at distinct G1 checkpoints. Oncogene. 1996, 13: 599-608.
Rodrigues EG, Travassos LR: Endogenous accumulation of IFN-gamma in IFN-gamma-R(-/-) mice increases resistance to B16F10-Nex2 murine melanoma: a model for direct IFN-gamma anti-tumor cytotoxicity in vitro and in vivo. Cytokines Cell Mol Ther. 2002, 7: 107-116. 10.1080/13684730310000121.
Harvat BL, Jetten AM: Gamma-interferon induces an irreversible growth arrest in mid-G1 in mammary epithelial cells which correlates with a block in hyperphosphorylation of retinoblastoma. Cell Growth Differ. 1996, 7: 289-300.
Mirjolet JF, Didelot C, Barberi-Heyob M, Merlin JL: G(1)/S but not G(0)/G(1) cell fraction is related to 5-fluorouracil cytotoxicity. Cytometry. 2002, 48: 6-13. 10.1002/cyto.10087.
Xu JM, Azzariti A, Tommasi S, Lacalamita R, Colucci G, Johnston PG, Church SW, Paradiso A: Combination of 5-fluorouracil and irinotecan on modulation of thymidylate synthase and topoisomerase I expression and cell cycle regulation in human colon cancer LoVo cells: clinical relevance. Clin Colorectal Cancer. 2002, 2: 182-188.
Kim EJ, Lee JM, Namkoong SE, Um SJ, Park JS: Interferon regulatory factor-1 mediates interferon-γ-induced apoptosis in ovarian carcinoma cells. J Cellular Biochem. 2002, 85: 369-380. 10.1002/jcb.10142.
Nagata S: FAS-induced apoptosis. Intern Med. 1998, 37: 179-181.
Read SB, Kulprathipanja NV, Gomez GG, Paul DB, Winston KR, Robbins JM, Kruse CA: Human alloreactive CTL interactions with gliomas and with those having upregulated HLA expression from exogenous IFN-gamma or IFN-gamma gene modification. J Interferon Cytokine Res. 2003, 23: 379-393. 10.1089/107999003322226032.
Tamura T, Ueda S, Yoshia M, Matsuzaki M, Mohri H, Okubo T: Interferon-gamma induces Ice gene expression and enhances cellular susceptibility to apoptosis in the U937 leukemia cell line. Biochem Biophys Res Commun. 1996, 229: 21-26. 10.1006/bbrc.1996.1752.
Detjen KM, Kehrberger JP, Drost A, Rabien A, Welzel M, Wiedenmann B, Rosewicz S: Interferon-gamma inhibits growth of human neuroendocrine carcinoma cells via induction of apoptosis. Int J Oncol. 2002, 21: 1133-1140.
Tamura T, Ishihara M, Lamphier MS, Tanaka N, Oishi I, Aizawa S, Matsuyama T, Mak TW, Taki S, Taniguchi T: DNA damage-induced apoptosis and Ice gene induction in mitogenically activated T lymphocytes require IRF-1. Leukemia. 1997, 11 (Suppl 3): 439-440.
Horiuchi M, Yamada H, Akishita M, Ito M, Tamura K, Dzau VJ: Interferon regulatory factors regulate interleukin-1 beta-converting enzym expression and apoptosis in vascular smooth muscle cells. Hypertension. 1999, 33: 162-169.
Chin YE, Kitagawa M, Kuida K, Flavell RA, Fu XY: Activation of the STAT signaling pathway can cause expression of caspase-1 and apoptosis. Mol Cell Biol. 1997, 17: 5328-5337.
Chen XX, Lai MD, Zhang YL, Huang Q: Less cytotoxicity to combination therapy of 5-fluorouracil and cisplatin than 5-fluorouracil alone in human colon cancer cell lines. World J Gastroenterol. 2002, 8: 841-846.
Eisenhofer G: The role of neuronal and extraneuronal plasma membrane transporters in the inactivation of peripheral catecholamines. Pharmacol Ther. 2001, 91: 35-62. 10.1016/S0163-7258(01)00144-9.
The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/4/23/prepub
We thank Antje Krahn and B. Ergün for excellent technical assistance. We are indebted to the Institute of Physiology, Charité University Medicine Berlin, Germany, for laboratory facilities. This study was supported by grants of the Deutsche Forschungsgemeinschaft and the Sonnenfeld-Stiftung.
MH : writing, study design, experimental design, investigation of growth inhibition and apoptosis; APS: cell cycle analysis by flow cytometry; AH: cytotoxicity studies; G A-H: RT-PCR, interpretation of the data; HS: study design, writing. All authors read and approved the final manuscript.
Authors’ original submitted files for images
Below are the links to the authors’ original submitted files for images.
About this article
Cite this article
Höpfner, M., Sutter, A.P., Huether, A. et al. A novel approach in the treatment of neuroendocrine gastrointestinal tumors: Additive antiproliferative effects of interferon-γ and meta-iodobenzylguanidine. BMC Cancer 4, 23 (2004). https://doi.org/10.1186/1471-2407-4-23
- Interferon Regulatory Factor
- Gastrointestinal Tumor
- Norepinephrine Transporter
- Neuroendocrine Tumor Cell
- Neuroendocrine Gastrointestinal Tumor